MET Exon 14 Skipping Mutation

Loading variant…

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Lung Non-Small Cell Carcinoma1
NOT MET Amplification AND MET Exon 14 Skipping Mutation	Cabozantinib + CrizotinibSequential	Predictive	C	Supports Sensitivity Response	2	submitted	EID11390 A 65-year old white male (non-smoker) developed recurrent metastatic NSCLC 17 months after lobectomy for stage IA disease. Genomic profiling showed MET exon 14 skipping mutation without MET amplificat… (full text at CIViC) PMID 27693535 · Klempner et al., 2017 · Open in CIViC	civic
Lung Sarcomatoid Carcinoma5
MET Amplification AND MET Exon 14 Skipping Mutation	Crizotinib	Predictive	C	Supports Sensitivity Response	3	submitted	EID11375 A 74-year-old woman with stage II Pulmonary Sarcomatoid Carcinoma (PSC) was treated with neoadjuvant platinum/taxane chemotherapy with no improvement. Chemotherapy was stopped due to resistance and po…

Molecular profile

Therapy

Type

Level

Direction · significance

Rating (1–5)

Status

Evidence

Source

Lung Non-Small Cell Carcinoma1

NOT MET Amplification AND MET Exon 14 Skipping Mutation

Cabozantinib + CrizotinibSequential

Predictive

Supports Sensitivity Response

submitted

EID11390

A 65-year old white male (non-smoker) developed recurrent metastatic NSCLC 17 months after lobectomy for stage IA disease. Genomic profiling showed MET exon 14 skipping mutation without MET amplificat… (full text at CIViC)

PMID 27693535 · Klempner et al., 2017 · Open in CIViC

civic

Lung Sarcomatoid Carcinoma5

MET Amplification AND MET Exon 14 Skipping Mutation

Crizotinib

Predictive

Supports Sensitivity Response

submitted

EID11375

A 74-year-old woman with stage II Pulmonary Sarcomatoid Carcinoma (PSC) was treated with neoadjuvant platinum/taxane chemotherapy with no improvement. Chemotherapy was stopped due to resistance and po…

Malignant Colorectal Neoplasm2
MET Exon 14 Skipping Mutation	Crizotinib	Predictive	B	Supports Sensitivity Response	3	submitted	EID11379 4 patient-derived cell lines with MET exon 14 skipping mutation were selected from 50 patient derived tumor lines from the SMC Biomarker study. These cell lines tested against crizotinib, which showed… (full text at CIViC) PMID 26375439 · Lee et al., 2015 · Open in CIViC	civic
MET Exon 14 Skipping Mutation	SAIT301	Predictive	B	Supports Sensitivity Response	3	submitted	EID11380 4 patient-derived cell lines with MET exon 14 skipping mutation were selected from 50 patient derived tumor lines from the SMC Biomarker study. These cell lines tested against SAIT301, a monoclonal an… (full text at CIViC) PMID 26375439 · Lee et al., 2015 · Open in CIViC	civic

Malignant Colorectal Neoplasm2

MET Exon 14 Skipping Mutation

Crizotinib

Predictive

Supports Sensitivity Response

submitted

EID11379

4 patient-derived cell lines with MET exon 14 skipping mutation were selected from 50 patient derived tumor lines from the SMC Biomarker study. These cell lines tested against crizotinib, which showed… (full text at CIViC)

PMID 26375439 · Lee et al., 2015 · Open in CIViC

civic

MET Exon 14 Skipping Mutation

SAIT301

Predictive

Supports Sensitivity Response

submitted

EID11380

4 patient-derived cell lines with MET exon 14 skipping mutation were selected from 50 patient derived tumor lines from the SMC Biomarker study. These cell lines tested against SAIT301, a monoclonal an… (full text at CIViC)

PMID 26375439 · Lee et al., 2015 · Open in CIViC

civic

Malignant Gastric Neoplasm3
MET Exon 14 Skipping Mutation	Crizotinib	Predictive	B	Supports Sensitivity Response	4	submitted	EID11377 4 patient-derived cell lines with MET exon 14 skipping mutation were selected from 50 patient derived tumor lines from the SMC Biomarker study. These cell lines tested against crizotinib, which showed… (full text at CIViC) PMID 26375439 · Lee et al., 2015 · Open in CIViC	civic
MET Exon 14 Skipping Mutation	SAIT301	Predictive	B	Supports Sensitivity Response	3	submitted	EID11378 4 patient-derived cell lines with MET exon 14 skipping mutation were selected from 50 patient derived tumor lines from the SMC Biomarker study. These cell lines tested against SAIT301, a monoclonal an… (full text at CIViC) PMID 26375439 · Lee et al., 2015 · Open in CIViC	civic
NOT MET Amplification AND MET Exon 14 Skipping Mutation	(prognostic)	Prognostic	C	Supports Poor Outcome	3	submitted	EID11381 A 27-year old male patient displayed poorly differentiated gastric adenocarcinoma and massive malignant ascites. Shortly after his diagnosis, the patient died. After genomic sequencing, it was shown t… (full text at CIViC) PMID 26375439 · Lee et al., 2015 · Open in CIViC	civic

Malignant Gastric Neoplasm3

MET Exon 14 Skipping Mutation

Crizotinib

Predictive

Supports Sensitivity Response

submitted

EID11377

PMID 26375439 · Lee et al., 2015 · Open in CIViC

civic

MET Exon 14 Skipping Mutation

SAIT301

Predictive

Supports Sensitivity Response

submitted

EID11378

PMID 26375439 · Lee et al., 2015 · Open in CIViC

civic

NOT MET Amplification AND MET Exon 14 Skipping Mutation

(prognostic)

Prognostic

Supports Poor Outcome

submitted

EID11381

A 27-year old male patient displayed poorly differentiated gastric adenocarcinoma and massive malignant ascites. Shortly after his diagnosis, the patient died. After genomic sequencing, it was shown t… (full text at CIViC)

PMID 26375439 · Lee et al., 2015 · Open in CIViC

civic

Malignant Lung Neoplasm1
MET Exon 14 Skipping Mutation	Capmatinib	Predictive	C	Supports Adverse Response	3	submitted	EID11459 An 84-year old man (smoker) presented with non-small-cell and small-cell lung cancer harboring MET exon 14 skipping mutations and brain metastases. Patient developed progression after eight months of … (full text at CIViC) PMID 34118303 · Mohan et al., 2022 · Open in CIViC	civic

Malignant Lung Neoplasm1

MET Exon 14 Skipping Mutation

Capmatinib

Predictive

Supports Adverse Response

submitted

EID11459

An 84-year old man (smoker) presented with non-small-cell and small-cell lung cancer harboring MET exon 14 skipping mutations and brain metastases. Patient developed progression after eight months of … (full text at CIViC)

PMID 34118303 · Mohan et al., 2022 · Open in CIViC

civic

Malignant Neoplasm2
MET Exon 14 Skipping Mutation	Capmatinib	Predictive	D	Supports Sensitivity Response	3	accepted	EID7797 MET exon 14 skipping was modelled in vitro by expressing human MET cDNA with exon 14 deletion in HEK293 cells and mouse MET with homologous exon 15 deletion in NIH3T3 cells. NIH3T3 cells expressing ME… (full text at CIViC) PMID 25971938 · Frampton et al., 2015 · Open in CIViC	civic
MET Exon 14 Skipping Mutation	Crizotinib	Predictive	D	Supports Sensitivity Response	3	accepted	EID736 The creation of a cell line model (HEK293) with MET exon 14 deletion (using the CRISPR/Cas9 system) led to enhanced cellular growth and sensitivity to the MET inhibitor crizotinib. MET exon 14 deletio… (full text at CIViC) PMID 26547802 · Togashi et al., 2015 · Open in CIViC	civic

Malignant Neoplasm2

MET Exon 14 Skipping Mutation

Capmatinib

Predictive

Supports Sensitivity Response

accepted

EID7797

MET exon 14 skipping was modelled in vitro by expressing human MET cDNA with exon 14 deletion in HEK293 cells and mouse MET with homologous exon 15 deletion in NIH3T3 cells. NIH3T3 cells expressing ME… (full text at CIViC)

PMID 25971938 · Frampton et al., 2015 · Open in CIViC

civic

MET Exon 14 Skipping Mutation

Crizotinib

Predictive

Supports Sensitivity Response

accepted

EID736

The creation of a cell line model (HEK293) with MET exon 14 deletion (using the CRISPR/Cas9 system) led to enhanced cellular growth and sensitivity to the MET inhibitor crizotinib. MET exon 14 deletio… (full text at CIViC)

PMID 26547802 · Togashi et al., 2015 · Open in CIViC

civic

Histiocytic And Dendritic Cell Cancer1unmapped disease
MET Exon 14 Skipping Mutation	Crizotinib	Predictive	C	Supports Sensitivity Response	3	accepted	EID7796 An 84 year old never-smoker with an upper chest mass was found to have stage 3 histiocytic sarcoma. Genomic profiling discovered a MET exon 14 variant c.2888-5_2944del62, as well as TP53 p.R175H and Z… (full text at CIViC) PMID 25971938 · Frampton et al., 2015 · Open in CIViC	civic

Histiocytic And Dendritic Cell Cancer1unmapped disease

MET Exon 14 Skipping Mutation

Crizotinib

Predictive

Supports Sensitivity Response

accepted

EID7796

An 84 year old never-smoker with an upper chest mass was found to have stage 3 histiocytic sarcoma. Genomic profiling discovered a MET exon 14 variant c.2888-5_2944del62, as well as TP53 p.R175H and Z… (full text at CIViC)

PMID 25971938 · Frampton et al., 2015 · Open in CIViC

civic

Unmapped disease3unmapped disease
MET Exon 14 Skipping Mutation	(functional)	Functional	D	Supports Gain Of Function	3	submitted	EID12840 Human embryonic kidney 293T cells were used in far-Western analysis experiments, which showed that Y1003 binds directly to the c-Cbl TKB domain in MET. When Y1003 was replaced with a non-phosphorylata… (full text at CIViC) PMID 15123609 · Peschard et al., 2004 · Open in CIViC	civic
MET Exon 14 Skipping Mutation AND MET Splice Site (c.3028+1G>T)	(functional)	Functional	B	Supports Gain Of Function	3	submitted	EID12839 1141 patients with lung cancer were analyzed using NGS, to which MET exon 14 mutations were found in 28 (3.0%) of them. Of the 28, 24 samples had RNA available for qRT-PCR for MET splicing. 23/24 (96%… (full text at CIViC) PMID 26729443 · Awad et al., 2016 · Open in CIViC	civic
MET Exon 14 Skipping Mutation AND ( MET Splice Site (c.3028+1G>T) OR MET Splice Site (c.3028+1G>A) OR MET Splice Site (c.3028+1G>C) )	(functional)	Functional	B	Supports Gain Of Function	3	submitted	EID12831 In this retrospective study, 564 NSCLC patients with somatic MET mutations were analyzed. There were 117 cases of METex14 skipping that were further sequenced. 75/117 cases (64.1%) affect the splicing… (full text at CIViC) PMID 35860830 · Ai et al., 2022 · Open in CIViC	civic

Unmapped disease3unmapped disease

MET Exon 14 Skipping Mutation

(functional)

Functional

Supports Gain Of Function

submitted

EID12840

Human embryonic kidney 293T cells were used in far-Western analysis experiments, which showed that Y1003 binds directly to the c-Cbl TKB domain in MET. When Y1003 was replaced with a non-phosphorylata… (full text at CIViC)

PMID 15123609 · Peschard et al., 2004 · Open in CIViC

civic

MET Exon 14 Skipping Mutation AND MET Splice Site (c.3028+1G>T)

(functional)

Functional

Supports Gain Of Function

submitted

EID12839

1141 patients with lung cancer were analyzed using NGS, to which MET exon 14 mutations were found in 28 (3.0%) of them. Of the 28, 24 samples had RNA available for qRT-PCR for MET splicing. 23/24 (96%… (full text at CIViC)

PMID 26729443 · Awad et al., 2016 · Open in CIViC

civic

MET Exon 14 Skipping Mutation AND ( MET Splice Site (c.3028+1G>T) OR MET Splice Site (c.3028+1G>A) OR MET Splice Site (c.3028+1G>C) )

(functional)

Functional

Supports Gain Of Function

submitted

EID12831

In this retrospective study, 564 NSCLC patients with somatic MET mutations were analyzed. There were 117 cases of METex14 skipping that were further sequenced. 75/117 cases (64.1%) affect the splicing… (full text at CIViC)

PMID 35860830 · Ai et al., 2022 · Open in CIViC

civic

Evidence by cancer (68 items)

Clinical significance (0)